Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOXIRI and Bevacizumab in metastatic colorectal cancer
NCT04380103Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Apr 2020
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan, oxaliplatin, capecitabine, bevacizumab in colorectal adenocarcinoma, sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
irinotecanoxaliplatincapecitabinebevacizumab
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on NCT04380103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04380103.